NO20043181L - Fremgangsmate til gjenvinning og rensing av poxvira infiserte celler - Google Patents

Fremgangsmate til gjenvinning og rensing av poxvira infiserte celler

Info

Publication number
NO20043181L
NO20043181L NO20043181A NO20043181A NO20043181L NO 20043181 L NO20043181 L NO 20043181L NO 20043181 A NO20043181 A NO 20043181A NO 20043181 A NO20043181 A NO 20043181A NO 20043181 L NO20043181 L NO 20043181L
Authority
NO
Norway
Prior art keywords
virus
infected cells
purification
poxviral
recovery
Prior art date
Application number
NO20043181A
Other languages
English (en)
Other versions
NO335975B1 (no
Inventor
Karl Heller
Jutta Kramer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of NO20043181L publication Critical patent/NO20043181L/no
Publication of NO335975B1 publication Critical patent/NO335975B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Den foreliggende oppfinnelse angår en fremgangsmåte til gjenvinning av poxvira, særlig modifisert Vacciniavira Ankara (MVA) fra infiserte celler. I henhold til foreliggende oppfinnelse blir de virusinfiserte celler utsatt for en høytrykkshomogenisering for å oppnå et virusinneholdende homogenat. Det virusinneholdende homogenat kan utsettes for minst ett rensetrinn for å oppnå en poxvirusanriket fraksjon. Oppfinnelsen angår videre den virusinneholdende fraksjon og det virusinneholdende homogenat oppnådd ved fremgangsmåten i henhold til foreliggende oppfinnelse.
NO20043181A 2001-12-20 2004-07-19 Fremgangsmåte til gjenvinning av poxvira, poxvirusanriket fraksjon eller poxvirusinneholdende homogenat oppnådd ved denne fremgangsmåten og anvendelser derav. NO335975B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101928 2001-12-20
PCT/EP2002/014179 WO2003054175A1 (en) 2001-12-20 2002-12-13 Method for the recovery and purification of poxviruses from infected cells

Publications (2)

Publication Number Publication Date
NO20043181L true NO20043181L (no) 2004-07-19
NO335975B1 NO335975B1 (no) 2015-04-07

Family

ID=8160920

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043181A NO335975B1 (no) 2001-12-20 2004-07-19 Fremgangsmåte til gjenvinning av poxvira, poxvirusanriket fraksjon eller poxvirusinneholdende homogenat oppnådd ved denne fremgangsmåten og anvendelser derav.

Country Status (23)

Country Link
US (1) US7056723B2 (no)
EP (1) EP1407006B9 (no)
JP (2) JP5322252B2 (no)
KR (1) KR100947976B1 (no)
CN (1) CN1289663C (no)
AT (1) ATE302268T1 (no)
AU (1) AU2002352247B2 (no)
BR (1) BRPI0215003B1 (no)
CA (1) CA2467099C (no)
DE (1) DE60205631T2 (no)
DK (1) DK1407006T3 (no)
EA (1) EA006485B1 (no)
ES (1) ES2247404T3 (no)
HK (1) HK1071765A1 (no)
HU (1) HU227507B1 (no)
IL (2) IL161526A0 (no)
MX (1) MXPA04006001A (no)
NO (1) NO335975B1 (no)
NZ (1) NZ533586A (no)
PL (1) PL205929B1 (no)
SI (1) SI1407006T1 (no)
UA (1) UA77735C2 (no)
WO (1) WO2003054175A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05680B1 (et) 2000-11-23 2013-10-15 Bavarian Nordic A/S Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
WO2004022729A1 (en) 2002-09-05 2004-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
WO2006052826A2 (en) * 2004-11-05 2006-05-18 The Government Of The United States Of America As Represented By The Secretary Methods for preparing cells and viruses
US7625570B1 (en) * 2005-03-10 2009-12-01 The Regents Of The University Of California Methods for purifying adeno-associated virus
WO2008138533A1 (en) * 2007-05-14 2008-11-20 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8003363B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
KR20100113159A (ko) * 2008-02-12 2010-10-20 사노피 파스퇴르 리미티드 폭스바이러스 정제를 위해 이온 교환 및 겔 여과 크로마토그래피를 사용하는 방법
BRPI1007744A2 (pt) * 2009-05-12 2017-06-27 Transgene Sa método para a produção e purificação de um ortopoxvírus do tipo selvagem, ortopoxvírus do tipo selvagem, composição farmacêutica, uso de um ortopoxvírus do tipo selvagem e uso de uma linhagem de células aviárias imortalizadas
FR2953686B1 (fr) 2009-12-14 2012-11-02 Agronomique Inst Nat Rech Procede pour reduire la teneur bacterienne d'un milieu alimentaire et/ou biologique d'interet, contenant des gouttelettes lipidiques
CA2802430C (en) 2010-07-20 2021-07-20 Bavarian Nordic A/S Method for harvesting poxvirus
CN102353792A (zh) * 2011-07-07 2012-02-15 贵州大学 一种基于gpv p32蛋白的间接elisa试剂盒及制备方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US20210187100A1 (en) 2018-09-06 2021-06-24 Bavarian Nordic A/S Storage Improved Poxvirus Compositions
KR20220153587A (ko) 2020-03-12 2022-11-18 버베리안 노딕 에이/에스 폭스바이러스 안정성을 개선하는 조성물
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
CN115197966A (zh) * 2022-08-15 2022-10-18 深圳源兴基因技术有限公司 一种利用生物反应器大规模生产重组痘苗病毒载体的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB877898A (en) 1956-12-06 1961-09-20 Apv Co Ltd A new or improved method of liberating enzymes
JPS5328989B2 (no) 1974-05-27 1978-08-17
CH621573A5 (en) 1976-08-05 1981-02-13 Vnii Biosinteza Belkovykh Vesc Process for the continuous disintegration of microorganism cells and system for carrying out this process
JPS54154594A (en) 1978-05-25 1979-12-05 Sumitomo Chem Co Ltd Extraction of glucose isomerase
WO1991001367A1 (en) 1989-07-20 1991-02-07 Bioeng, Inc. Supercritical fluid disruption of and extraction from microbial cells
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
TW426733B (en) 1995-10-06 2001-03-21 Merck & Co Inc Method of disrupting cultured cells using an impinging jet device
US6869793B2 (en) * 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
US5721120A (en) 1996-10-02 1998-02-24 Merck & Co., Inc. Method of disrupting cultured cells using an impinging jet device
NZ299720A (en) * 1996-11-08 1999-07-29 Howick Engineering Ltd Epicyclic input/output annuli of same pcd, with planetary input/output gear sets, and with only one set having aligned teeth
KR100503701B1 (ko) * 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US6000551A (en) 1996-12-20 1999-12-14 Eastman Chemical Company Method for rupturing microalgae cells
FR2787465A1 (fr) * 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
DE60029195T2 (de) * 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
DE19918619A1 (de) 1999-04-23 2000-10-26 Rhein Biotech Proz & Prod Gmbh Verfahren zum Gewinnen von rekombinantem HBsAg
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen

Also Published As

Publication number Publication date
EA006485B1 (ru) 2005-12-29
UA77735C2 (en) 2007-01-15
EA200400833A1 (ru) 2004-12-30
WO2003054175A1 (en) 2003-07-03
HU227507B1 (hu) 2011-07-28
EP1407006B1 (en) 2005-08-17
KR20040070263A (ko) 2004-08-06
CA2467099A1 (en) 2003-07-03
BR0215003A (pt) 2004-11-09
EP1407006A1 (en) 2004-04-14
DE60205631T2 (de) 2006-06-08
MXPA04006001A (es) 2005-08-19
SI1407006T1 (sl) 2006-04-30
PL369498A1 (en) 2005-04-18
US20040265986A1 (en) 2004-12-30
AU2002352247A1 (en) 2003-07-09
DK1407006T3 (da) 2005-12-12
CA2467099C (en) 2013-01-29
JP2005512565A (ja) 2005-05-12
IL161526A (en) 2009-11-18
JP2010046093A (ja) 2010-03-04
HUP0402337A3 (en) 2010-01-28
BRPI0215003B1 (pt) 2017-03-14
US7056723B2 (en) 2006-06-06
NZ533586A (en) 2005-02-25
NO335975B1 (no) 2015-04-07
JP5322252B2 (ja) 2013-10-23
HK1071765A1 (en) 2005-07-29
ATE302268T1 (de) 2005-09-15
IL161526A0 (en) 2004-09-27
KR100947976B1 (ko) 2010-03-15
DE60205631D1 (de) 2005-09-22
AU2002352247B2 (en) 2008-08-07
ES2247404T3 (es) 2006-03-01
EP1407006B9 (en) 2006-10-18
PL205929B1 (pl) 2010-06-30
CN1606616A (zh) 2005-04-13
CN1289663C (zh) 2006-12-13
HUP0402337A2 (hu) 2005-01-28

Similar Documents

Publication Publication Date Title
NO20043181L (no) Fremgangsmate til gjenvinning og rensing av poxvira infiserte celler
SG156673A1 (en) Improved viral purification methods
DK2261378T3 (da) Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membranfusogene kappeproteiner
ATE521627T1 (de) Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
HK1080507A1 (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
FI20002720A (fi) Menetelmä konversioiden suorittamiseksi
ATE399210T1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
DK1337655T3 (da) Lentivirusvektorer til behandling af neurodegenerative sygdomme
He et al. Deep sequencing reveals a novel closterovirus associated with wild rose leaf rosette disease
NO20040222L (no) Peptider til fjerning eller destruksjon av celler
NO20045440L (no) Vannloselig polymerdispersjon og fremgangsmate for a fremstille en vannloselig polymerdispersjon
ES2170734A1 (es) Metodo para la preparacion de citalopram.
WO2002065834A3 (en) Novel formulations of carvedilol
DK1508047T3 (da) Fremgangsmåde til identifikation af immunoreaktive peptider
NO990375L (no) Anordning og fremgangsmåte for komprimering av våtgass
ATE313641T1 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
WO2001083710A3 (en) Clearance of neoplastic cells from mixed cellular compositions using viruses
BRPI0416950A8 (pt) métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida
Schlemmer et al. A unique, infectious RNA associated with citron showing symptoms typical of citrus exocortis disease.
ATE491952T1 (de) Screening auf inhibitoren des eindringens von hepatitis-c-virus
NO20023711L (no) Kokeprosess
CY1107922T1 (el) Μεθοδος για την παρασκευη 4-πενταφθοροσουλφανυλο-βενζοϋλογουανιδινων
Navarro et al. Identification of geminiviruses in woody plants through next generation sequencing.
Kagami et al. UV-A protection of white fabrics for photosensitive dermatoses
WO2001085770A3 (en) Sentinel virus ii

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees